Marjolein Lahaye

698 total citations
50 papers, 422 citations indexed

About

Marjolein Lahaye is a scholar working on Psychiatry and Mental health, Genetics and Surgery. According to data from OpenAlex, Marjolein Lahaye has authored 50 papers receiving a total of 422 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Psychiatry and Mental health, 16 papers in Genetics and 12 papers in Surgery. Recurrent topics in Marjolein Lahaye's work include Schizophrenia research and treatment (16 papers), Inflammatory Bowel Disease (15 papers) and Epilepsy research and treatment (8 papers). Marjolein Lahaye is often cited by papers focused on Schizophrenia research and treatment (16 papers), Inflammatory Bowel Disease (15 papers) and Epilepsy research and treatment (8 papers). Marjolein Lahaye collaborates with scholars based in Netherlands, Germany and Italy. Marjolein Lahaye's co-authors include A. Schreiner, Joop van Oene, Renzo Guerrini, S. Schwalen, Manuel Franco, Philip Gorwood, L. Hargarter, Kaire Aadamsoo, Mathias Zink and Adam Janik and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gastroenterology.

In The Last Decade

Marjolein Lahaye

47 papers receiving 419 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marjolein Lahaye Netherlands	10	265	69	65	62	60	50	422
Irena Lipshitz Israel	8	133 0.5×	33 0.5×	30 0.5×	58 0.9×	11 0.2×	9	319
N Nair India	13	85 0.3×	35 0.5×	69 1.1×	23 0.4×	10 0.2×	30	470
Verónica González Spain	12	113 0.4×	30 0.4×	9 0.1×	33 0.5×	28 0.5×	20	405
A.M. Crawford United States	9	537 2.0×	44 0.6×	253 3.9×	10 0.2×	111 1.9×	13	974
B. Wallin United States	11	288 1.1×	42 0.6×	17 0.3×	12 0.2×	59 1.0×	22	766
M. Giguère Canada	9	124 0.5×	15 0.2×	318 4.9×	100 1.6×	35 0.6×	14	679
Robin White United States	9	473 1.8×	130 1.9×	46 0.7×	14 0.2×	5 0.1×	13	571
Mat D. Davis United States	11	263 1.0×	30 0.4×	14 0.2×	13 0.2×	6 0.1×	36	616
Ammar Natalwala United Kingdom	7	119 0.4×	9 0.1×	20 0.3×	29 0.5×	6 0.1×	20	433
Andreu Massot‐Tarrús Spain	12	167 0.6×	74 1.1×	27 0.4×	3 0.0×	8 0.1×	24	278

Countries citing papers authored by Marjolein Lahaye

Since Specialization

Citations

This map shows the geographic impact of Marjolein Lahaye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marjolein Lahaye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marjolein Lahaye more than expected).

Fields of papers citing papers by Marjolein Lahaye

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marjolein Lahaye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marjolein Lahaye. The network helps show where Marjolein Lahaye may publish in the future.

Co-authorship network of co-authors of Marjolein Lahaye

This figure shows the co-authorship network connecting the top 25 collaborators of Marjolein Lahaye. A scholar is included among the top collaborators of Marjolein Lahaye based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marjolein Lahaye. Marjolein Lahaye is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Parmeggiani, Francesco, Dominique Brémond‐Gignac, Avril Daly, et al.. (2025). The burden of X-linked retinitis pigmentosa (XLRP) on patient experience and patient-reported outcomes (PROs): findings from the EXPLORE XLRP-2 study. Eye. 39(3). 578–585. 2 indexed citations

Parmeggiani, Francesco, Dominique Brémond‐Gignac, Avril Daly, et al.. (2025). The Impacts of Caregiving for Patients with X-Linked Retinitis Pigmentosa (XLRP): Findings from the EXPLORE XLRP-2 Study. Advances in Therapy. 42(6). 2922–2936.

Peyrin‐Biroulet, Laurent, Séverine Vermeire, Geert D’Haens, et al.. (2023). Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long‐term extension period of STARDUST. Alimentary Pharmacology & Therapeutics. 59(2). 175–185. 9 indexed citations

Panés, Julián, Séverine Vermeire, Geert D’Haens, et al.. (2023). Ustekinumab improves health‐related quality of life in patients with moderate‐to‐severe Crohn's disease: Results up to Week 104 of the STARDUST trial. United European Gastroenterology Journal. 11(5). 410–422. 6 indexed citations

Panaccione, Remo, Christopher Gasink, Timothy Hoops, et al.. (2022). O30 Closure of perianal fistula in patients receiving ustekinumab in the SEAVUE and STARDUST trials. Oral Presentations. A17–A17. 2 indexed citations

Peyrin‐Biroulet, Laurent, Séverine Vermeire, Geert D’Haens, et al.. (2022). DOP90 Efficacy of the treat-to-target approach in modifying disease course with ustekinumab in patients with moderate-to-severe Crohn’s Disease: Results from the STARDUST trial. Journal of Crohn s and Colitis. 16(Supplement_1). i132–i134. 2 indexed citations

Kucharzik, Torsten, Rune Wilkens, Maria Antonietta D’Agostino, et al.. (2021). S902 Intestinal Ultrasound Response and Transmural Remission After 48 Weeks of Treatment With Ustekinumab in Crohn’s Disease: STARDUST Trial Substudy Results by Line of Treatment and by Location. The American Journal of Gastroenterology. 116(1). S426–S426. 2 indexed citations

Danese, Silvio, Séverine Vermeire, Geert D’Haens, et al.. (2021). Sa073 USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: RESULTS FROM A WEEK 16 INTERIM ANALYSIS OF THE STARDUST TRIAL. Gastroenterology. 160(6). S–409. 1 indexed citations

Sánchez, Pedro, et al.. (2021). The Patient, Investigator, Nurse, Carer Questionnaire (PINC-Q): a cross-sectional, retrospective, non-interventional study exploring the impact of less frequent medication administration with paliperidone palmitate 3-monthly as maintenance treatment for schizophrenia. BMC Psychiatry. 21(1). 300–300. 10 indexed citations

10.

Danese, Silvio, Séverine Vermeire, Geert D’Haens, et al.. (2021). 105 CLINICAL AND ENDOSCOPIC RESPONSE TO TREAT-TO-TARGET VERSUS STANDARD OF CARE IN CROHN'S DISEASE PATIENTS TREATED WITH USTEKINUMAB: WEEK 48 RESULTS OF THE STARDUST TRIAL. Gastroenterology. 160(6). S–25. 4 indexed citations

11.

Jayaram, Anuradha, Anna Wingate, Daniel Wetterskog, et al.. (2021). Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial. Annals of Oncology. 32(6). 726–735. 36 indexed citations

12.

Vauth, Roland, et al.. (2020). Relationship between clinical outcomes measures and personal and social performance functioning in a prospective, interventional study in schizophrenia. International Journal of Methods in Psychiatric Research. 30(2). e1855–e1855. 9 indexed citations

13.

Kucharzik, Torsten, Rune Wilkens, Giovanni Maconi, et al.. (2020). Intestinal ultrasound response and transmural healing after ustekinumab induction in Crohn’s disease: Week 16 interim analysis of the STARDUST trial substudy. Zeitschrift für Gastroenterologie. 58. 1 indexed citations

14.

Kucharzik, Torsten, Rune Wilkens, Giovanni Maconi, et al.. (2020). DOP10 Intestinal ultrasound response and transmural healing after ustekinumab induction in Crohn’s disease: Week 16 interim analysis of the STARDUST trial substudy. Journal of Crohn s and Colitis. 14(Supplement_1). S046–S048. 10 indexed citations

15.

Schreiner, A., Kaire Aadamsoo, A.C. Altamura, et al.. (2015). Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophrenia Research. 169(1-3). 393–399. 115 indexed citations

16.

Naber, Dieter, Joseph Peuskens, Bruno Millet, et al.. (2014). Flexible-dose oral paliperidone ER in non-acute schizophrenia previously unsuccessfully treated with oral risperidone. Clinical Practice. 11(6). 573–583. 1 indexed citations

17.

Heres, Stephan, Leszek Bidzan, Michel Blanc, et al.. (2013). Treatment of acute schizophrenia with paliperidone ER: Predictors for treatment response and benzodiazepine use. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 48. 207–212. 13 indexed citations

18.

Schmauß, Max, Vlado Jukić, Alberto Siracusano, et al.. (2012). Flexible dosing with paliperidone ER in the treatment of patients with acutely exacerbated schizophrenia: results from a single-arm, open-label study. Current Medical Research and Opinion. 28(8). 1395–1404. 13 indexed citations

19.

Schreiner, A., Dagmar Hoeben, Marjolein Lahaye, et al.. (2011). Tolerability and treatment response in patients with recently diagnosed vs. chronic schizophrenia treated with paliperidone ER. European Psychiatry. 26(S2). 1503–1503. 2 indexed citations

20.

Guerrini, Renzo, Johannes A. Carpay, Joop van Oene, et al.. (2005). Topiramate monotherapy as broad-spectrum antiepileptic drug in a naturalistic clinical setting. Seizure. 14(6). 371–380. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact